Cargando…
Targeting NF-κB by the Cell-Permeable NEMO-Binding Domain Peptide Improves Albuminuria and Renal Lesions in an Experimental Model of Type 2 Diabetic Nephropathy
Diabetic nephropathy (DN) is a multifactorial disease characterized by hyperglycemia and close interaction of hemodynamic, metabolic and inflammatory factors. Nuclear factor-κB (NF-κB) is a principal matchmaker linking hyperglycemia and inflammation. The present work investigates the cell-permeable...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352510/ https://www.ncbi.nlm.nih.gov/pubmed/32545818 http://dx.doi.org/10.3390/ijms21124225 |
_version_ | 1783557654898016256 |
---|---|
author | Opazo-Ríos, Lucas Plaza, Anita Sánchez Matus, Yenniffer Bernal, Susana Lopez-Sanz, Laura Jimenez-Castilla, Luna Carpio, Daniel Droguett, Alejandra Mezzano, Sergio Egido, Jesús Gomez-Guerrero, Carmen |
author_facet | Opazo-Ríos, Lucas Plaza, Anita Sánchez Matus, Yenniffer Bernal, Susana Lopez-Sanz, Laura Jimenez-Castilla, Luna Carpio, Daniel Droguett, Alejandra Mezzano, Sergio Egido, Jesús Gomez-Guerrero, Carmen |
author_sort | Opazo-Ríos, Lucas |
collection | PubMed |
description | Diabetic nephropathy (DN) is a multifactorial disease characterized by hyperglycemia and close interaction of hemodynamic, metabolic and inflammatory factors. Nuclear factor-κB (NF-κB) is a principal matchmaker linking hyperglycemia and inflammation. The present work investigates the cell-permeable peptide containing the inhibitor of kappa B kinase γ (IKKγ)/NF-κB essential modulator (NEMO)-binding domain (NBD) as therapeutic option to modulate inflammation in a preclinical model of type 2 diabetes (T2D) with DN. Black and tan, brachyuric obese/obese mice were randomized into 4 interventions groups: Active NBD peptide (10 and 6 µg/g body weight); Inactive mutant peptide (10 µg/g); and vehicle control. In vivo/ex vivo fluorescence imaging revealed efficient delivery of NBD peptide, systemic biodistribution and selective renal metabolization. In vivo administration of active NBD peptide improved albuminuria (>40% reduction on average) and kidney damage, decreased podocyte loss and basement membrane thickness, and modulated the expression of proinflammatory and oxidative stress markers. In vitro, NBD blocked IKK-mediated NF-κB induction and target gene expression in mesangial cells exposed to diabetic-like milieu. These results constitute the first nephroprotective effect of NBD peptide in a T2D mouse model that recapitulates the kidney lesions observed in DN patients. Targeting IKK-dependent NF-κB activation could be a therapeutic strategy to combat kidney inflammation in DN. |
format | Online Article Text |
id | pubmed-7352510 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-73525102020-07-15 Targeting NF-κB by the Cell-Permeable NEMO-Binding Domain Peptide Improves Albuminuria and Renal Lesions in an Experimental Model of Type 2 Diabetic Nephropathy Opazo-Ríos, Lucas Plaza, Anita Sánchez Matus, Yenniffer Bernal, Susana Lopez-Sanz, Laura Jimenez-Castilla, Luna Carpio, Daniel Droguett, Alejandra Mezzano, Sergio Egido, Jesús Gomez-Guerrero, Carmen Int J Mol Sci Article Diabetic nephropathy (DN) is a multifactorial disease characterized by hyperglycemia and close interaction of hemodynamic, metabolic and inflammatory factors. Nuclear factor-κB (NF-κB) is a principal matchmaker linking hyperglycemia and inflammation. The present work investigates the cell-permeable peptide containing the inhibitor of kappa B kinase γ (IKKγ)/NF-κB essential modulator (NEMO)-binding domain (NBD) as therapeutic option to modulate inflammation in a preclinical model of type 2 diabetes (T2D) with DN. Black and tan, brachyuric obese/obese mice were randomized into 4 interventions groups: Active NBD peptide (10 and 6 µg/g body weight); Inactive mutant peptide (10 µg/g); and vehicle control. In vivo/ex vivo fluorescence imaging revealed efficient delivery of NBD peptide, systemic biodistribution and selective renal metabolization. In vivo administration of active NBD peptide improved albuminuria (>40% reduction on average) and kidney damage, decreased podocyte loss and basement membrane thickness, and modulated the expression of proinflammatory and oxidative stress markers. In vitro, NBD blocked IKK-mediated NF-κB induction and target gene expression in mesangial cells exposed to diabetic-like milieu. These results constitute the first nephroprotective effect of NBD peptide in a T2D mouse model that recapitulates the kidney lesions observed in DN patients. Targeting IKK-dependent NF-κB activation could be a therapeutic strategy to combat kidney inflammation in DN. MDPI 2020-06-13 /pmc/articles/PMC7352510/ /pubmed/32545818 http://dx.doi.org/10.3390/ijms21124225 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Opazo-Ríos, Lucas Plaza, Anita Sánchez Matus, Yenniffer Bernal, Susana Lopez-Sanz, Laura Jimenez-Castilla, Luna Carpio, Daniel Droguett, Alejandra Mezzano, Sergio Egido, Jesús Gomez-Guerrero, Carmen Targeting NF-κB by the Cell-Permeable NEMO-Binding Domain Peptide Improves Albuminuria and Renal Lesions in an Experimental Model of Type 2 Diabetic Nephropathy |
title | Targeting NF-κB by the Cell-Permeable NEMO-Binding Domain Peptide Improves Albuminuria and Renal Lesions in an Experimental Model of Type 2 Diabetic Nephropathy |
title_full | Targeting NF-κB by the Cell-Permeable NEMO-Binding Domain Peptide Improves Albuminuria and Renal Lesions in an Experimental Model of Type 2 Diabetic Nephropathy |
title_fullStr | Targeting NF-κB by the Cell-Permeable NEMO-Binding Domain Peptide Improves Albuminuria and Renal Lesions in an Experimental Model of Type 2 Diabetic Nephropathy |
title_full_unstemmed | Targeting NF-κB by the Cell-Permeable NEMO-Binding Domain Peptide Improves Albuminuria and Renal Lesions in an Experimental Model of Type 2 Diabetic Nephropathy |
title_short | Targeting NF-κB by the Cell-Permeable NEMO-Binding Domain Peptide Improves Albuminuria and Renal Lesions in an Experimental Model of Type 2 Diabetic Nephropathy |
title_sort | targeting nf-κb by the cell-permeable nemo-binding domain peptide improves albuminuria and renal lesions in an experimental model of type 2 diabetic nephropathy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352510/ https://www.ncbi.nlm.nih.gov/pubmed/32545818 http://dx.doi.org/10.3390/ijms21124225 |
work_keys_str_mv | AT opazorioslucas targetingnfkbbythecellpermeablenemobindingdomainpeptideimprovesalbuminuriaandrenallesionsinanexperimentalmodeloftype2diabeticnephropathy AT plazaanita targetingnfkbbythecellpermeablenemobindingdomainpeptideimprovesalbuminuriaandrenallesionsinanexperimentalmodeloftype2diabeticnephropathy AT sanchezmatusyenniffer targetingnfkbbythecellpermeablenemobindingdomainpeptideimprovesalbuminuriaandrenallesionsinanexperimentalmodeloftype2diabeticnephropathy AT bernalsusana targetingnfkbbythecellpermeablenemobindingdomainpeptideimprovesalbuminuriaandrenallesionsinanexperimentalmodeloftype2diabeticnephropathy AT lopezsanzlaura targetingnfkbbythecellpermeablenemobindingdomainpeptideimprovesalbuminuriaandrenallesionsinanexperimentalmodeloftype2diabeticnephropathy AT jimenezcastillaluna targetingnfkbbythecellpermeablenemobindingdomainpeptideimprovesalbuminuriaandrenallesionsinanexperimentalmodeloftype2diabeticnephropathy AT carpiodaniel targetingnfkbbythecellpermeablenemobindingdomainpeptideimprovesalbuminuriaandrenallesionsinanexperimentalmodeloftype2diabeticnephropathy AT droguettalejandra targetingnfkbbythecellpermeablenemobindingdomainpeptideimprovesalbuminuriaandrenallesionsinanexperimentalmodeloftype2diabeticnephropathy AT mezzanosergio targetingnfkbbythecellpermeablenemobindingdomainpeptideimprovesalbuminuriaandrenallesionsinanexperimentalmodeloftype2diabeticnephropathy AT egidojesus targetingnfkbbythecellpermeablenemobindingdomainpeptideimprovesalbuminuriaandrenallesionsinanexperimentalmodeloftype2diabeticnephropathy AT gomezguerrerocarmen targetingnfkbbythecellpermeablenemobindingdomainpeptideimprovesalbuminuriaandrenallesionsinanexperimentalmodeloftype2diabeticnephropathy |